Company / Capital Expenditures
Sana Biotechnology, Inc. Capital Expenditures History
FY2019-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$33.4M
FY2024
5-year range
$20.0M / $33.4M
FY2020-FY2024
Trend
+66.9%
vs FY2023
Sector context
#34 of 194
Health Care
What the data says
Sana Biotechnology, Inc.'s capital expenditures of $33M is higher than 82% of companies in the Health Care sector (FY2024). Capital Expenditures returned to growth in FY2024 after 2 years of decline, reaching $33M.
Based on SEC 10-K filings.
$33M in FY2024 with a 5-year CAGR of +5.1%. Top quartile in the Health Care sector.
Improved from $21M to $33M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +3.8%
- 5-Year CAGR
- +5.1%
- 10-Year CAGR
- -
Sector benchmark
-71.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.1%, indicating consistent growth.
- In FY2024, capital expenditures increased 66.9% year-over-year.
- Ranks #34 out of 194 companies in the Health Care sector.
- Lowest capital expenditures in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $33.4M | +66.9% |
| FY2023 | $20.0M | -4.0% |
| FY2022 | $20.9M | -30.1% |
| FY2021 | $29.9M | +25.1% |
| FY2020 | $23.9M | -8.6% |
| FY2019 | $26.1M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026